Gardiquimod
 | |
| Systematic (IUPAC) name | |
|---|---|
|
1-(4-Amino-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol | |
| Identifiers | |
| CAS Number | 1020412-43-4 |
| Chemical data | |
| Formula | C17H23N5O |
| Molar mass | 313.40 g·mol−1 |
  (what is this?) (verify) | |
Gardiquimod is a selective compound for mouse or human toll-like receptor 7 (TLR7) and acts as an immune response modifier.[1][2][3] The core structure is 1H-imidazo[4,5-c]quinoline like in both imiquimod and resiquimod. It is structurally extremely similar to resiquimod differing only by an oxygen for nitrogen switch.
References
- ↑ NCBI: “The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice”
- ↑ NCBI: Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells
- ↑ Nature.com: “Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells”
This article is issued from Wikipedia - version of the Friday, February 26, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.